Bibliographies thématiques / White asnestos and BRCA

Sommaire

Articles de revues
Actes de conférences

Littérature scientifique sur le sujet « White asnestos and BRCA »

Auteur : Grafiati

Publié le 7 juin 2025

Mis à jour le 2 août 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « White asnestos and BRCA ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "White asnestos and BRCA"

Mahaparea, APK., G. Srinivas, D.V. Ramanjaneyulu, et al. "An Important Parameters of Benign Mesothelioma Include Etiology, Histopathology, Pathophysiology, Diagnosis, Differential Diagnosis and Treatment." Journal of Research and Applications in Pharmacy Practices 1, no. 1 (2025): 7–16. https://doi.org/10.5281/zenodo.15362187.

Texte intégral

Résumé :

<em>Usually found in the pleura, but occasionally occurring in the peritoneum, pericardium, and other tissues, benign mesothelioma is an uncommon, non-cancerous tumour that develops from mesothelial cells that coat the surfaces of many organs. Benign types of mesotheliomas do not have a proven connection to asbestos exposure, in contrast to malignant forms. In any case, they could arise as a result of other stressors, such as inflammation or mechanical damage.</em> <em>Patients usually have vague symptoms when they first arrive, such as chest pain, abdomen pain, and maybe a pleural effusion. H

Styles APA, Harvard, Vancouver, ISO, etc.

Wu, YN, CL Thompson, and FR Schumacher. "Epigenetic Aging Differs By Race, Subtype and Social Vulnerability Index in Breast Cancer Patients." Cancer Epidemiology, Biomarkers & Prevention 32, no. 6 (2023): 861. http://dx.doi.org/10.1158/1055-9965.epi-23-0366.

Texte intégral

Résumé :

Purpose: Although breast cancer (BrCa) disparities by age of onset, subtype and mortality are well recognized between Black and White women, the underlying causes remain unknown. We were interested in the impact of methylation on racial disparities, BrCa subtypes and social vulnerability index (SVI). Methods: A whole-genome methylation array was used with DNA extracted from blood samples from women diagnosed with BrCa. After quality control, 158 BrCa patients were included. The biological age and epigenetic age acceleration, defined as the residual from regressing chronological and biological

Styles APA, Harvard, Vancouver, ISO, etc.

Wu, Yanning, Megan E. Miller, Hannah L. Gilmore, Cheryl L. Thompson, and Fredrick R. Schumacher. "Epigenetic aging differentially impacts breast cancer risk by self-reported race." PLOS ONE 19, no. 10 (2024): e0308174. http://dx.doi.org/10.1371/journal.pone.0308174.

Texte intégral

Résumé :

Background Breast cancer (BrCa) is the most common cancer for women globally. BrCa incidence varies by age and differs between racial groups, with Black women having an earlier age of onset and higher mortality compared to White women. The underlying biological mechanisms of this disparity remain uncertain. Here, we address this knowledge gap by examining the association between overall epigenetic age acceleration and BrCa initiation as well as the mediating role of race. Results We measured whole-genome methylation (866,238 CpGs) using the Illumina EPIC array in blood DNA extracted from 209 w

Styles APA, Harvard, Vancouver, ISO, etc.

Wang, Haocen, Lei-Shih Chen, Hsin-Yi Hsiao, et al. "Chinese American and Non-Hispanic White Breast Cancer Patients’ Knowledge and Use of BRCA Testing." International Journal of Environmental Research and Public Health 20, no. 4 (2023): 3384. http://dx.doi.org/10.3390/ijerph20043384.

Texte intégral

Résumé :

Breast cancer is the most commonly diagnosed cancer among Chinese American women. Knowing the BRCA1 and BRCA2 (BRCA1/2) gene mutation status can improve breast cancer patients’ health outcomes by guiding targeted treatment towards preventing breast cancer recurrence and other BRCA-related cancers. Nevertheless, it is unclear if there is a disparity in knowledge and use of BRCA testing among Chinese American breast cancer patients. This cross-sectional study investigated the possible presence of differences in the knowledge and the use of BRCA testing between Chinese American and Non-Hispanic W

Styles APA, Harvard, Vancouver, ISO, etc.

Wu, Yanning, Cheryl L. Thompson, and Fredrick R. Schumacher. "Abstract 3676: Race-specific methylation profiles and epigenetic age acceleration differentiates estrogen receptor status breast cancer." Cancer Research 82, no. 12_Supplement (2022): 3676. http://dx.doi.org/10.1158/1538-7445.am2022-3676.

Texte intégral

Résumé :

Abstract Breast cancer (BrCa) is the second most common cancer among women in the U.S.. Black women with BrCa, on average, have an earlier age of onset, more aggressive subtypes and experience higher mortality compared with White women. Although the underlying causes remain unknown, genetic and lifetime exposures are hypothesized. Here, we utilize blood-based whole-genome methylation arrays to: (1) discover CpG probes related to BrCa receptor status, (2) identify biological pathways driving BrCa subtype disparities, and (3) quantify epigenetic age acceleration differences by race and receptor

Styles APA, Harvard, Vancouver, ISO, etc.

Jin, Yanling, Charlotta Fruchtenicht, Sylvia Hu, et al. "Association of electronic-health record (EHR)-derived race with BRCA testing in patients (pts) with breast cancer (BC) with similar genetic ancestry (GA) in a clinicogenomic database (CGDB)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 6524. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.6524.

Texte intégral

Résumé :

6524 Background: Disparities in health outcomes can be affected by biological factors associated with GA and social determinants of health. These factors can be teased apart using GA data from comprehensive genomic profiling (CGP) in pts with cancer. CGDBs that link EHR data with CGP enable the selection of pts with similar GA. Holding GA constant provides an opportunity to directly study the effects of reported race in health disparities. This study evaluated a published racial disparity (BRCA testing rates in African American [AA] vs White pts with BC) in a population with fixed, similar GA.

Styles APA, Harvard, Vancouver, ISO, etc.

Kyaw, Nay Yee Wint, Theresa Durana, Vijaya Natarajan, and Yiqing Xu. "The race, staging and clinical correlations with genetic mutations detected in breast cancer patients." Journal of Clinical Oncology 41, no. 16_suppl (2023): e12547-e12547. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e12547.

Texte intégral

Résumé :

e12547 Background: Genetic testing has been applied widely in oncology and guidelines and criteria have been established for selection of testing. We aimed to study the variants of genetic mutations detected in a cohort of breast cancer patients of multiple ethnicity background, and its pathoclinical correlations. Methods: Breast cancer patients who have had a genetic test performed between 1/1/2010 until 1/31/2022 were eligible. Results: Among 767 patients tested, 77 patients were found to have germline mutations, including BRCA 1 (n = 20), BRCA 2 (n = 19), PALB2 (n = 12), CHEK 2 (n = 6), ATM

Styles APA, Harvard, Vancouver, ISO, etc.

Sims, Travis T., Anil K. Sood, Shannon Neville Westin, et al. "Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer." Journal of Clinical Oncology 39, no. 15_suppl (2021): 5568. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5568.

Texte intégral

Résumé :

5568 Background: Nearly 50% of patients with high grade ovarian cancer (HGOC) harbor a germline or somatic mutation in BRCA1/BRCA2 or have tumors characterized by homologous recombination deficiency (HRD). HRD is associated with response to poly(ADP-ribose) polymerase inhibitors (PARPi) in HGOC. Although PARPi show great promise, there is interest in investigating how HRD status affects outcomes and can be used to objectively tailor other treatment strategies. We aimed to compare clinical and survival outcomes in HGOC stratified by HRD status. Methods: We performed a retrospective analysis of

Styles APA, Harvard, Vancouver, ISO, etc.

Law, Jeanna Wallenta, Hanadi BuAli, Sherri Costa, et al. "Abstract P3-14-17: Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis." Cancer Research 82, no. 4_Supplement (2022): P3–14–17—P3–14–17. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-14-17.

Texte intégral

Résumé :

Abstract Background and Objective: BRCA testing for patients (pts) with triple negative breast cancer (TNBC) is important because it has secondary prevention implications for patients and multigenerational implications allowing for earlier detection of BRCA gene carriers in the family and enabling primary prevention. And with the advent of PARP inhibitors it also has treatment implications. The NCCN guidelines recommended in January 2015 that BRCA testing be performed for all pts with TNBC diagnosed at age 60 or younger regardless of race, ethnicity or family history. To understand disparities

Styles APA, Harvard, Vancouver, ISO, etc.

Hall, Michael J., and Olufunmilayo I. Olopade. "Disparities in Genetic Testing: Thinking Outside the BRCA Box." Journal of Clinical Oncology 24, no. 14 (2006): 2197–203. http://dx.doi.org/10.1200/jco.2006.05.5889.

Texte intégral

Résumé :

The impact of predictive genetic testing on cancer care can be measured by the increased demand for and utilization of genetic services as well as in the progress made in reducing cancer risks in known mutation carriers. Nonetheless, differential access to and utilization of genetic counseling and cancer predisposition testing among underserved racial and ethnic minorities compared with the white population has led to growing health care disparities in clinical cancer genetics that are only beginning to be addressed. Furthermore, deficiencies in the utility of genetic testing in underserved po

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Actes de conférences sur le sujet "White asnestos and BRCA"

Green, Matthew, Hannah Ngo, Dakota B. Pastore, et al. "Addressing Gaps in Care Through a Medical Student-Led Cancer Screening Project." In 28th Annual Rowan-Virtua Research Day. Rowan University Libraries, 2024. http://dx.doi.org/10.31986/issn.2689-0690_rdw.stratford_research_day.35_2024.

Texte intégral

Résumé :

Background: Colorectal cancer (CRC), breast cancer (BrCa), and cervical cancer are three of the most preventable cancers. Despite the known significance for early detection and treatment, barriers to screening remain. We developed a medical student-led project to improve adherence to national cancer screening guidelines in patients across Rowan-Virtua Family Medicine (FM) practices. This study assesses the initiative’s efficacy in improving adherence to CRC, BrCa, and cervical cancer screenings. Methods: Rowan-Virtua FM patients between the ages of 21-75 (n=735) were identified as due or up-to

Styles APA, Harvard, Vancouver, ISO, etc.

Marques, Lays Costa, Ana Claudia Gonçalves Lima, Nilceana Maya Aires Freitas, et al. "Olaparib in the treatment of leptomeningeal carcinomatosis." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1064.

Texte intégral

Résumé :

Leptomeningeal carcinomatosis (LC) is a complication of breast cancer that carries a poor prognosis. The median overall survival was only 3.8 months. Due to the scarcity of data on therapeutic interventions, patterns of practice vary widely. Preclinical studies have shown that PARP inhibitors penetrate the central nervous system, suggesting a possible role in treatment. We report a case of a patient with BRCA2 and LC mutation who demonstrated an excellent clinical response to Olaparib. A woman had classic lobular carcinoma in the right breast at the age of 50 years. Immunohistochemistry was po

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!